Movement Alert｜Revolution Medicines, Inc. Intraday Rise 5.43% in Regular Trading, Phase 3 Lung Cancer Combination Trial Begins Dosing Patients

Market Focus10-20

On October 20, Revolution Medicines, Inc. rose 5.43% in Regular Trading, trading at $191.36 per share, with turnover of $64.69 million.

The move followed the company’s announcement that it has begun treating patients in the Phase 3 RASolve 308 trial evaluating zoldonrasib in combination with pembrolizumab and chemotherapy as a first-line treatment for metastatic RAS G12D non-squamous non-small cell lung cancer.

The update adds to a series of recent pipeline and commercial catalysts. Earlier this month, the company also started patient dosing in the Phase 3 RASolute 309 trial in first-line metastatic RAS G12D pancreatic cancer, while recent analyst commentary highlighted encouraging early uptake for Rasonque after its August FDA approval in pancreatic cancer, including expectations for about $36 million of third-quarter revenue from the launch. Together, these developments reinforced investor expectations for both near-term commercialization and longer-term label expansion through combination therapies and earlier-line treatment settings.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1150070264?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-20 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150070264","market":"us","top_or_hot":-1,"title":"Movement Alert｜Revolution Medicines, Inc. Intraday Rise 5.43% in Regular Trading, Phase 3 Lung Cancer Combination Trial Begins Dosing Patients","media":"Market Focus","content":"<p><p>On October 20, Revolution Medicines, Inc. rose 5.43% in Regular Trading, trading at $191.36 per share, with turnover of $64.69 million.</p><p>The move followed the company’s announcement that it has begun treating patients in the Phase 3 RASolve 308 trial evaluating zoldonrasib in combination with pembrolizumab and chemotherapy as a first-line treatment for metastatic RAS G12D non-squamous non-small cell lung cancer.</p><p>The update adds to a series of recent pipeline and commercial catalysts. Earlier this month, the company also started patient dosing in the Phase 3 RASolute 309 trial in first-line metastatic RAS G12D pancreatic cancer, while recent analyst commentary highlighted encouraging early uptake for Rasonque after its August FDA approval in pancreatic cancer, including expectations for about $36 million of third-quarter revenue from the launch. Together, these developments reinforced investor expectations for both near-term commercialization and longer-term label expansion through combination therapies and earlier-line treatment settings.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Revolution Medicines, Inc. Intraday Rise 5.43% in Regular Trading, Phase 3 Lung Cancer Combination Trial Begins Dosing Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Revolution Medicines, Inc. Intraday Rise 5.43% in Regular Trading, Phase 3 Lung Cancer Combination Trial Begins Dosing Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-20 22:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 20, Revolution Medicines, Inc. rose 5.43% in Regular Trading, trading at $191.36 per share, with turnover of $64.69 million.</p><p>The move followed the company’s announcement that it has begun treating patients in the Phase 3 RASolve 308 trial evaluating zoldonrasib in combination with pembrolizumab and chemotherapy as a first-line treatment for metastatic RAS G12D non-squamous non-small cell lung cancer.</p><p>The update adds to a series of recent pipeline and commercial catalysts. Earlier this month, the company also started patient dosing in the Phase 3 RASolute 309 trial in first-line metastatic RAS G12D pancreatic cancer, while recent analyst commentary highlighted encouraging early uptake for Rasonque after its August FDA approval in pancreatic cancer, including expectations for about $36 million of third-quarter revenue from the launch. Together, these developments reinforced investor expectations for both near-term commercialization and longer-term label expansion through combination therapies and earlier-line treatment settings.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVMD","symbol_name":"Revolution Medicines, Inc.","start_time":0,"source_url":"","article_id":"1150070264","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150070264","pubTimestamp":1792505114,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 20, Revolution Medicines, Inc. rose 5.43% in Regular Trading, trading at $191.36 per share, with turnover of $64.69 million.The move followed the company’s announcement that it has begun...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RVMD":"Revolution Medicines, Inc."},"translate_title":"走势警报|Revolution Medicines, Inc. 常规交易盘中上涨 5.43%，3 期肺癌联合试验开始给患者给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVMD":1},"content_text":"On October 20, Revolution Medicines, Inc. rose 5.43% in Regular Trading, trading at $191.36 per share, with turnover of $64.69 million.The move followed the company’s announcement that it has begun treating patients in the Phase 3 RASolve 308 trial evaluating zoldonrasib in combination with pembrolizumab and chemotherapy as a first-line treatment for metastatic RAS G12D non-squamous non-small cell lung cancer.The update adds to a series of recent pipeline and commercial catalysts. Earlier this month, the company also started patient dosing in the Phase 3 RASolute 309 trial in first-line metastatic RAS G12D pancreatic cancer, while recent analyst commentary highlighted encouraging early uptake for Rasonque after its August FDA approval in pancreatic cancer, including expectations for about $36 million of third-quarter revenue from the launch. Together, these developments reinforced investor expectations for both near-term commercialization and longer-term label expansion through combination therapies and earlier-line treatment settings.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1150070264","isCrawlerRequest":true}